10 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 10 separate news trends connected to Obesity Drug, spanning June 23, 2026 through October 20, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 84 article observations and 77 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
Novo's next-generation obesity drug surprises with 25% weight loss in women, despite demand concerns.
Injectable CBL‑514 slashes visceral fat in a Phase 2 trial, sparking fresh debate on non‑surgical obesity solutions.
Roche’s sudden halt of its muscle‑sparing obesity antibody reverberates through patients, investors and the biotech pipeline.
Experimental weight-loss shot yields promising results, raising hopes for obesity treatment
Viking Therapeutics stock surges 30% on positive obesity drug trial results.
Roche's obesity drug shows promise in mid-stage trial with significant weight loss and improved blood sugar control.
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
Amgen's decision to drop an obesity drug in phase 1 trials has intensified competition in the pharmaceutical sector.
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.